Skip to content
GERICLINICS

Flashcards · Module 41

💊 Deprescribing Frameworks & Specific Tapering Protocols

4 of 4 cards published · read by the site’s author on 22 November 2026

PPI Deprescribing Algorithm: Escaping the rebound acid trap

Needs clinical review

The Overuse Epidemic:

In one cohort of hospitalised older adults, 62.4% of those on drugs for ulcer or reflux were inappropriately treated (often started as stress ulcer prophylaxis in hospital and never stopped!).

Possible Harms of Long-Term PPIs (small, but higher in older people):

  • 🦠 Infections: C. difficile colitis (pooled risk 1.69), hospital-acquired pneumonia.

  • 🦴 Fractures: Inhibits calcium and magnesium absorption → accelerated osteoporosis and hip fractures.

  • 🧪 Nutritional Deficits: Vitamin B12 malabsorption, hypomagnesemia.

  • 🫘 Renal: Acute interstitial nephritis (AIN) and chronic kidney disease.

The Rebound Acid Hypersecretion Trap:

Stopping a PPI abruptly can cause rebound acid hypersecretion from a compensatory rise in acid production. The patient experiences burning reflux and assumes they "need the pill forever."

How to Deprescribe (Canadian guideline):

  1. Lower the daily dose, or stop and use it on demand, once symptoms have resolved after at least 4 weeks of treatment.

  2. Or switch to an H2-receptor antagonist (a weaker suggestion).

  3. Not for Barrett's oesophagus, severe (grade C or D) oesophagitis or a past bleeding ulcer.

One-Liner: Once reflux symptoms have resolved after at least 4 weeks, lower the PPI dose, stop it or switch to on-demand use (not in Barrett's, severe oesophagitis or a past bleeding ulcer); rebound symptoms may follow.
Sources checked (11) · 21 November 2026

Note: The Canadian guideline notes that rebound symptoms are hard to tell from returning reflux, and that their clinical significance is unknown. (Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline (2017))

Antihypertensive Deprescribing in Frailty & Low DBP

Needs clinical review

The J-Curve Phenomenon in Geriatric Blood Pressure:

Lower is NOT always better in frail older adults!

Why Low Diastolic Blood Pressure (DBP) is Deadly:

  • Coronary arteries fill predominantly during diastole!

  • In older adults with stiff, calcified aorta, wide pulse pressure is common (e.g., BP 150/55).

  • Lowering systolic BP aggressively can push diastolic BP to levels that may compromise myocardial perfusion.

  • Diastolic BP below 60 mmHg has been linked to subclinical myocardial damage, coronary events and death (observational data).

  • In SPRINT's oldest participants, intensive control brought slightly more hypotension (2.4% vs 1.4%) and syncope (3.0% vs 2.4%), differences that were not statistically significant.

When to Deprescribe Antihypertensives:

  1. Low systolic BP (below 130 mmHg in the PARTAGE nursing-home study) while on two or more BP drugs, in a frail patient.

  2. Diastolic BP < 60 mmHg.

  3. Significant symptomatic orthostatic hypotension (SBP drop ≥20 mmHg).

  4. SPRINT-Senior showed tight control helps fit elders, but multimorbid nursing home residents were excluded from those trials.

One-Liner: In frail older adults, consider reducing BP medicines when diastolic BP is below 60 mmHg, systolic BP is low on several drugs, or orthostatic hypotension appears; the thresholds rest on observational data.
Sources checked (6) · 21 November 2026

Antipsychotic Tapering in Dementia: Escaping the chemical restraint

Needs clinical review

The CMS Mandate:

US nursing home rules (CMS) call for gradual dose reduction (GDR) or discontinuation of antipsychotics.

When Can You Safely Deprescribe?

If an older adult with dementia was started on an antipsychotic (e.g., Risperidone, Quetiapine) for agitation or psychosis, attempt deprescribing after at least 3 months of treatment (symptoms stable, or no response).

The Tapering Protocol:

  • Taper slowly: e.g., reduce the dose by 25% to 50% every 1 to 2 weeks (clinicians piloting the guideline preferred slower).

  • Prefer a slow taper to stopping abruptly.

  • Watch for symptoms returning: in most trials, outcomes did not differ between stopping and continuing.

The Evidence:

Clinical trials (like the DART-AD study) show that deprescribing antipsychotics in dementia does not, on average, worsen behavioural symptoms, with no consistent change in cognition in most patients!

One-Liner: After at least 3 months of treatment for BPSD, taper antipsychotics slowly (e.g., 25–50% every 1–2 weeks); on average, symptoms do not worsen.
Sources checked (5) · 21 November 2026

Benzodiazepine & Z-Drug Slow Tapers: The Ashton Protocol

Needs clinical review

Why Benzodiazepines Are Risky in Older Adults:

Benzos (Lorazepam, Alprazolam) and Z-drugs (Zolpidem) cause:

  • Increased hip fracture risk (RR 1.34 in one meta-analysis) and falls

  • 60% to 80% increased traffic accident risk (OR 1.59–1.81)

  • Cognitive problems

  • Physical dependence

The Ashton Tapering Strategy:

  1. Switching to a long half-life agent (diazepam) is optional: it has not been shown to reduce withdrawal symptoms or improve success more than tapering the original drug.

  2. The "Turtle Taper": reduce by about 25% every 2 weeks, slowing to 12.5% steps near the end, then planned drug-free days.

  3. Behavioral Support: add CBT for insomnia: it improves stopping rates over tapering alone, though the gain fades in the long term.

One-Liner: Offer every older adult on a benzodiazepine or Z-drug a slow taper (about 25% every 2 weeks, 12.5% near the end), with CBT for insomnia if available; switching to diazepam is optional.
Sources checked (5) · 21 November 2026

Note: Ashton's approach uses diazepam for convenience of dosage strengths, but tapering can be done directly from the original drug. (The treatment of benzodiazepine dependence (1994))